ArticleNeurourology and urodynamics2022
SUFU white paper on overactive bladder anticholinergic medications and dementia risk.
Article in Neurourology and urodynamics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate for Mixed Lower Urinary Tract Symptoms
Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Using intravesical botulinum toxin as an adjunct during urologic surgery: a systematic review.World journal of urology · 2026Pooled it
- Risk of dementia in patients treated with anticholinergics for overactive bladder syndrome: a systematic review and meta-analysis.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Pooled it
- Efficacy and Safety of Vibegron for Persistent Symptoms of Overactive Bladder in Men Being Pharmacologically Treated for Benign Prostatic Hyperplasia: Results From the Phase 3 Randomized Controlled COURAGE Trial.The Journal of urology · 2024Trial
- Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.World journal of urology · 2024Trial
- Bladder Antimuscarinic Use and Cognitive Impairment in Adults Aged 75 Years or Older With Urinary Incontinence or Overactive Bladder Symptoms: A Population-Based Study.Pharmacoepidemiology and drug safety · 2026Article
- Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review.Advances in therapy · 2026Review
- Peroneal electrical transcutaneous neuromodulation (peroneal eTNMWorld journal of urology · 2026Review
- Review
- Navigating the challenges of overactive bladder management in women.World journal of urology · 2026Review
- Diagnosis and management of urinary incontinence in females.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Review
- Article
- Trospium Chloride in the Treatment of Overactive Bladder Syndrome and Detrusor Overactivity.Advances in therapy · 2025Review
- Specialist Practices for Managing Persons Living with Dementia and Urinary Incontinence.International urogynecology journal · 2025Article
- The Fluid Connection: Balancing Hydration and Overactive Bladder Symptoms in Women.International urogynecology journal · 2025Article
- Outcomes of Sacral Neuromodulation and Intradetrusor Onabotulinum Toxin in the Management of Stroke Associated Urinary Incontinence.International neurourology journal · 2025Article
- Outcomes following intradetrusor onabotulinumtoxinA in a national cohort of nursing home residents.BJUI compass · 2025Article
- Implantable Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Single-Institution Retrospective Study.International neurourology journal · 2024Article
- Urologic care of nonagenarians A retrospective chart review.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Article
- Sacral neuromodulation in nursing home residents: Predictors of success and complications in a national cohort of older adults.Neurourology and urodynamics · 2024Article
- Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsAnticholinergic medications are widely used in the treatment of overactive bladder (OAB), as well as for short-term treatment of bladder symptoms following a variety of urologic surgeries. Mounting evidence points to an association between anticholinergic medications and the increased risk of incident dementia. The Society for Urodynamics, Female Pelvic Medicine, and Urogenital Reconstruction (SUFU) thus convened a committee of subject experts to contextualize the current understanding of the cognitive risks of anticholinergic medications in the urologic patient population and to provide practical clinical guidance on this subject.
methodsStatements are based on an expert literature review and the committee's opinion. The document has been reviewed and approved by the SUFU board.
resultsChronic use (>3 months) of OAB anticholinergic medications is likely associated with an increased risk of new-onset dementia. Short-term (<4 weeks) use of most OAB anticholinergic medications is likely safe in most individuals. Clinicians should consider potential cognitive risks in all patient populations when prescribing OAB anticholinergics for chronic use. Consideration should be given to progressing to advanced therapy (botulinum toxin or neuromodulation) earlier in the OAB treatment paradigm
conclusionsThe current body of literature supports a likely small but significant increased risk of dementia with chronic exposure to OAB anticholinergic medications. Potential harms should be balanced against potential quality of life improvement with treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.